155 related articles for article (PubMed ID: 30538425)
1. Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product.
Singh SK; Pokalwar S; Bose S; Gupta S; Almal S; Ranbhor RS
Biologics; 2018; 12():159-170. PubMed ID: 30538425
[TBL] [Abstract][Full Text] [Related]
2. Analytical characterization of recombinant hCG and comparative studies with reference product.
Thennati R; Singh SK; Nage N; Patel Y; Bose SK; Burade V; Ranbhor RS
Biologics; 2018; 12():23-35. PubMed ID: 29430170
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
5. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Assessing analytical comparability of biosimilars: GCSF as a case study.
Nupur N; Singh SK; Narula G; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
[TBL] [Abstract][Full Text] [Related]
10. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.
Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ
J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212
[TBL] [Abstract][Full Text] [Related]
11. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches.
Li C; Rossomando A; Wu SL; Karger BL
MAbs; 2013; 5(4):565-75. PubMed ID: 23751726
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
13. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
[TBL] [Abstract][Full Text] [Related]
14. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
15. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
[TBL] [Abstract][Full Text] [Related]
16. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab.
Zhang Z; Perrault R; Zhao Y; Ding J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():148-57. PubMed ID: 27038651
[TBL] [Abstract][Full Text] [Related]
17. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
19. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
[TBL] [Abstract][Full Text] [Related]
20. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
